Suppr超能文献

硼替佐米治疗特发性膜性肾病所致肾病综合征。

Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.

作者信息

Hartono Choli, Chung Miriam, Kuo Sheng F, Seshan Surya V, Muthukumar Thangamani

机构信息

The Rogosin Institute, 505 East 70th Street, Box 102, New York, NY, 10021, USA,

出版信息

J Nephrol. 2014 Feb;27(1):103-6. doi: 10.1007/s40620-013-0028-x. Epub 2014 Jan 16.

Abstract

Idiopathic membranous nephropathy is a common cause of nephrotic syndrome in adults. The nephrotic syndrome due to idiopathic membranous nephropathy is often resistant to glucocorticosteroids and requires an alkylating agent such as chlorambucil or cyclophosphamide to induce remission. Recent studies illustrate that antibodies against the autoantigen M-type phospholipase A2 receptor contribute to a vast majority but not all cases of idiopathic membranous nephropathy. Herein, we report a patient with nephrotic syndrome due to membranous nephropathy that was resistant to 6 months of therapy with ramipril and high-dose glucocorticosteroids but responded to a single cycle of bortezomib infusion.

摘要

特发性膜性肾病是成人肾病综合征的常见病因。由特发性膜性肾病引起的肾病综合征通常对糖皮质激素耐药,需要使用诸如苯丁酸氮芥或环磷酰胺等烷化剂来诱导缓解。最近的研究表明,针对自身抗原M型磷脂酶A2受体的抗体在绝大多数但并非所有特发性膜性肾病病例中起作用。在此,我们报告一名因膜性肾病导致肾病综合征的患者,该患者对雷米普利和高剂量糖皮质激素治疗6个月耐药,但对单周期硼替佐米输注有反应。

相似文献

1
Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy.
J Nephrol. 2014 Feb;27(1):103-6. doi: 10.1007/s40620-013-0028-x. Epub 2014 Jan 16.
5
Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Pediatr Nephrol. 2018 Jun;33(6):1089-1092. doi: 10.1007/s00467-018-3923-5. Epub 2018 Mar 15.
10
[Membranous nephropathy: New insights in therapeutic approach].
Nephrol Ther. 2017 Apr;13 Suppl 1:S83-S87. doi: 10.1016/j.nephro.2017.02.002.

引用本文的文献

1
Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.
Clin Kidney J. 2025 Mar 21;18(5):sfaf088. doi: 10.1093/ckj/sfaf088. eCollection 2025 May.
2
Therapeutic targets in membranous nephropathy: plasma cells and complement.
Clin Kidney J. 2024 Aug 13;17(9):sfae243. doi: 10.1093/ckj/sfae243. eCollection 2024 Sep.
3
Infectious Disease Prophylaxis During and After Immunosuppressive Therapy.
Kidney Int Rep. 2024 Apr 25;9(8):2337-2352. doi: 10.1016/j.ekir.2024.04.043. eCollection 2024 Aug.
4
Membranous nephropathy: pathogenesis and treatments.
MedComm (2020). 2024 Jun 29;5(7):e614. doi: 10.1002/mco2.614. eCollection 2024 Jul.
5
How to Choose the Right Treatment for Membranous Nephropathy.
Medicina (Kaunas). 2023 Nov 14;59(11):1997. doi: 10.3390/medicina59111997.
6
Clinical advances in immunotherapy for immune-mediated glomerular diseases.
Clin Exp Med. 2023 Dec;23(8):4091-4105. doi: 10.1007/s10238-023-01218-7. Epub 2023 Oct 27.
7
Treatment of membranous nephropathy: Perspectives on current and future therapies.
Front Nephrol. 2023 Jan 27;3:1110355. doi: 10.3389/fneph.2023.1110355. eCollection 2023.
8
Future landscape for the management of membranous nephropathy.
Clin Kidney J. 2023 Mar 10;16(8):1228-1238. doi: 10.1093/ckj/sfad041. eCollection 2023 Aug.
9
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.
Drugs. 2023 Apr;83(6):507-530. doi: 10.1007/s40265-023-01855-y. Epub 2023 Apr 5.

本文引用的文献

1
Glomerular diseases: membranous nephropathy--a modern view.
Clin J Am Soc Nephrol. 2014 Mar;9(3):609-16. doi: 10.2215/CJN.04160413. Epub 2013 Jun 27.
2
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.
Lancet. 2013 Mar 2;381(9868):744-51. doi: 10.1016/S0140-6736(12)61566-9. Epub 2013 Jan 9.
3
ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura.
N Engl J Med. 2013 Jan 3;368(1):90-2. doi: 10.1056/NEJMc1213206.
4
Rituximab in idiopathic membranous nephropathy.
J Am Soc Nephrol. 2012 Aug;23(8):1416-25. doi: 10.1681/ASN.2012020181. Epub 2012 Jul 19.
5
Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy.
Clin J Am Soc Nephrol. 2012 Sep;7(9):1394-400. doi: 10.2215/CJN.02170312. Epub 2012 Jul 5.
6
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.
J Am Soc Nephrol. 2011 Aug;22(8):1543-50. doi: 10.1681/ASN.2010111125. Epub 2011 Jul 22.
7
Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.
J Am Soc Nephrol. 2010 Apr;21(4):697-704. doi: 10.1681/ASN.2009080861. Epub 2010 Jan 28.
8
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.
N Engl J Med. 2009 Jul 2;361(1):11-21. doi: 10.1056/NEJMoa0810457.
9
Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.
Am J Transplant. 2009 Jan;9(1):201-9. doi: 10.1111/j.1600-6143.2008.02461.x. Epub 2008 Oct 31.
10
IgA nephropathy in a patient with IgG lambda light-chain plasmacytoma: a rare coincidence.
Nephrol Dial Transplant. 2007 Sep;22(9):2705-8. doi: 10.1093/ndt/gfm351. Epub 2007 Jun 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验